Nonetheless, we have provided it here to help to illustrate that the strategy can be effective when it used in
combination with price action.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations
with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and
price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government
action that could have the effect of lowering
prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in
combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock
price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed
with the U.S. Securities and Exchange Commission (the SEC).
Combination of economic trends and policies Still, for now an array of Obama administration
actions and economic trends are conspiring to cut emissions, according to EIA: Americans are using less oil because of high gasoline
prices; carmakers are complying
with federal fuel economy standards; electricity companies are becoming more efficient; state renewable energy rules are ushering wind and solar energy onto the power grids; gas
prices are competitive
with coal; and federal air quality regulations are closing the dirtiest power plants.
This group of traders use all of the techniques of the first school of
price action traders, yet they often combine
price action with indicators like the stochastic oscillator, RSI, MACD, bollinger bands, etc... and many
combinations of western indicators.
In closing, I would just like to say that I get feedback from my member's all the time; emails and testimonials from people who truly are turning the corner in their trading, not because they are professional full - time traders, but because they have stopped the bleeding and are starting to see the power of effective money management and
price action trading in
combination with one another.
Combine that
with a valid
price action strategy and the right amount of bullish or bearish momentum, and you have a winning
combination.
One thing that isn't a mystery is that Fibonacci retracement levels work and can be extremely beneficial, but only when used properly and in
combination with other trading strategies like those found
with price action.
Now for the really fun part — using these levels in
combination with what we already know about
price action.
Always use the Fibonacci tool in
combination with other
price action strategies and techniques.
This is the power of using a simple
price action pattern in
combination with a higher time frame such as the 4 - hour chart.